source
- FDA cites Baxter’s inadequate oversight after repeated GMP violations at multiple plantsThe U.S. Food and Drug Administration has issued a warning letter to Baxter International, saying the company's leadership has failed to provide adequate oversight of its drug manufacturing operati…
- Arcus kidney cancer drug shows stronger potency than Merck's Welireg, boosting sharesArcus Biosciences reported follow‑up data from its late‑stage kidney cancer trial that suggest its experimental therapy, casdatifan, may be more potent than Merck's approved drug Welireg. Analysts…